Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers
- PMID: 6318655
- PMCID: PMC185930
- DOI: 10.1128/AAC.24.5.713
Intranasal interferon as protection against experimental respiratory coronavirus infection in volunteers
Abstract
In a double-blind, placebo-controlled study, self-administered intranasal human interferon alpha A produced by recombinant DNA technology was given both before and after virus challenge with a respiratory coronavirus. The incidence of colds, the severity of symptoms and signs, and virus replication were all reduced in subjects receiving interferon as compared with those given placebo.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
